Icariin plus TACE to prevent liver cancer return
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking icariin soft capsules along with a liver-directed treatment called TACE can help prevent liver cancer from coming back after surgery or ablation. It is for people who have had their tumor removed but still have risk factors that make recurrence more likely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with hepatocellular carcinoma (HCC) and have fully recovered from surgery or a tumor-removal procedure.
- You have at least one high-risk feature that makes your cancer more likely to come back, such as a tumor larger than 5 cm, multiple tumors, or cancer that spread into blood vessels or lymph nodes.
- Your liver function is still relatively good (Child-Pugh A or early B).
- You have no major vein blockages (like in the main portal vein) and no active hepatitis B (viral level under 500 IU/mL).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control while on the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
This trial tests whether adding an oral herbal medicine (Icaritin) to standard combination therapy (TACE, immunotherapy, and targeted therapy) works better than the standard combination alone for advanced liver cancer that cannot be removed with surgery. It may be a good option if you haven't had whole-body cancer treatment before and your liver is still working well.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a new immunotherapy drug (ivonescimab) combined with TACE (a procedure that blocks blood flow to the tumor) for people with liver cancer that cannot be surgically removed. It aims to see if adding the immunotherapy can help control the cancer better than TACE alone.
Hear when a new Hepatocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.